Saltar al contenido
Merck

T7080

Tazarotene

≥98% (HPLC), prodrug of tazarotenic acid, powder

Sinónimos:

6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester, AGN-190168, ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula empírica (notación de Hill):
C21H21NO2S
Número CAS:
118292-40-3
Peso molecular:
351.46
UNSPSC Code:
12352200
NACRES:
NA.77

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Tazarotene, ≥98% (HPLC)

SMILES string

S1CCC(c2c1ccc(c2)C#Cc3ncc(cc3)C(=O)OCC)(C)C

InChI

1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3

InChI key

OGQICQVSFDPSEI-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to very faintly yellow

solubility

DMSO: >15 mg/mL

originator

Allergan

storage temp.

2-8°C

Quality Level

100

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene.
Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene. It is a prodrug of tazarotenic acid, which specifically activates RARb and RARg, only weakly activates RARa, and is inactive at retinoid X receptors (RXRs). In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Allergan. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361d

Hazard Classifications

Repr. 2

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
106M4755V
085M4707V
021M4717V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

M Lebwohl
Journal of the American Academy of Dermatology, 43(2 Pt 3), S43-S46 (2000-07-18)
In the treatment of plaque psoriasis with corticosteroids, long-term efficacy and safety are often compromised by tachyphylaxis, steroid rebound, and adverse effects. However, the results of recent studies demonstrate that the use of tazarotene in conjunction with a corticosteroid can
D D Tang-Liu et al.
Clinical pharmacokinetics, 37(4), 273-287 (1999-12-20)
Tazarotene (AGN 190168) is a new acetylenic retinoid which is effective for the topical treatment of patients with stable plaque psoriasis and mild to moderate acne vulgaris. Topical gel application provides direct delivery of tazarotene into the skin. At 10
A Roeder et al.
Skin pharmacology and physiology, 17(3), 111-118 (2004-04-17)
Tazarotene is a member of the new generation of receptor-selective, synthetic retinoids for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris and photoaging. Though they are effective in monotherapy, clinical studies with a focus on novel combination
Mark A Hyde et al.
Archives of dermatology, 148(5), 592-596 (2012-03-21)
To determine if the complete response rates of lentigo maligna (LM) to imiquimod, 5%, cream can be improved by the addition of a topical retinoid. Prospective randomized study of patients treated with imiquimod alone vs imiquimod plus a topical retinoid
Ritu Saini et al.
Current pharmaceutical design, 11(2), 273-280 (2005-01-11)
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico